132 related articles for article (PubMed ID: 21159055)
1. Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin.
Hamuro A; Saito S
Psychogeriatrics; 2010 Dec; 10(4):198-200. PubMed ID: 21159055
[TBL] [Abstract][Full Text] [Related]
2. Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice.
Hayashi Y; Ishida Y; Inoue T; Udagawa M; Takeuchi K; Yoshimuta H; Kiue K; Ninomiya Y; Kawano J; Sameshima T; Kawahara T; Goto I; Shudo K; Kurayama S; Nakamura J; Okahara K; Mitsuyama Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):541-5. PubMed ID: 20184936
[TBL] [Abstract][Full Text] [Related]
3. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
Paleacu D; Barak Y; Mirecky I; Mazeh D
Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
[TBL] [Abstract][Full Text] [Related]
4. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease.
Monji A; Takita M; Samejima T; Takaishi T; Hashimoto K; Matsunaga H; Oda M; Sumida Y; Mizoguchi Y; Kato T; Horikawa H; Kanba S
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):308-11. PubMed ID: 19138715
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
6. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease.
Hashimoto M; Yatabe Y; Kaneda K; Honda K; Ikeda M
Psychogeriatrics; 2009 Dec; 9(4):196-203. PubMed ID: 20377821
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer's disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial.
Suzuki H; Gen K
Psychogeriatrics; 2015 Mar; 15(1):32-7. PubMed ID: 25516380
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
[TBL] [Abstract][Full Text] [Related]
9. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
10. Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living.
Yoon JS; Kim JM; Lee H; Shin IS; Choi SK
Hum Psychopharmacol; 2003 Dec; 18(8):627-33. PubMed ID: 14696022
[TBL] [Abstract][Full Text] [Related]
11. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.
De Deyn PP; Wirshing WC
J Clin Psychiatry; 2001; 62 Suppl 21():19-22. PubMed ID: 11584983
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
Onor ML; Saina M; Trevisiol M; Cristante T; Aguglia E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):205-9. PubMed ID: 17020789
[TBL] [Abstract][Full Text] [Related]
13. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease.
Okahara K; Ishida Y; Hayashi Y; Inoue T; Tsuruta K; Takeuchi K; Yoshimuta H; Kiue K; Ninomiya Y; Kawano J; Yoshida K; Noda S; Tomita S; Fujimoto M; Hosomi J; Mitsuyama Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):532-6. PubMed ID: 20170698
[TBL] [Abstract][Full Text] [Related]
14. Category verbal fluency predicted changes in behavioral and psychological symptoms of dementia in patients with Alzheimer's disease.
Tsai CF; Wang SJ; Zheng L; Fuh JL
Psychiatry Clin Neurosci; 2010 Aug; 64(4):408-14. PubMed ID: 20573053
[TBL] [Abstract][Full Text] [Related]
15. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
[TBL] [Abstract][Full Text] [Related]
16. Behavioural and neuropsychological correlates of frontal lobe features in dementia.
Engelborghs S; Maertens K; Mariën P; Vloeberghs E; Somers N; Nagels G; De Deyn PP
Psychol Med; 2006 Aug; 36(8):1173-82. PubMed ID: 16700962
[TBL] [Abstract][Full Text] [Related]
17. [Dementia following bipolar disorder].
Lebert F; Lys H; Haëm E; Pasquier F
Encephale; 2008 Dec; 34(6):606-10. PubMed ID: 19081458
[TBL] [Abstract][Full Text] [Related]
18. Estrogen replacement therapy: effects on the cognitive functioning and clinical course of women with Alzheimer's disease.
Levine AJ; Battista M
Arch Clin Neuropsychol; 2004 Sep; 19(6):769-78. PubMed ID: 15288330
[TBL] [Abstract][Full Text] [Related]
19. Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease.
Mauri M; Mancioli A; Rebecchi V; Corbetta S; Colombo C; Bono G
Acta Neurol Scand; 2006 Aug; 114(2):97-101. PubMed ID: 16867031
[TBL] [Abstract][Full Text] [Related]
20. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
